Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses: 2013-2024

Historic Change in Accured Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to $21.6 million.

  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses rose 18.07% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 61.13%. This contributed to the annual value of $21.6 million for FY2024, which is 331.64% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Change in Accured Expenses stood at $21.6 million for FY2024, which was up 331.64% from $5.0 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses peaked at $21.6 million during FY2024, and registered a low of $1.4 million during FY2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses averaged around $11.5 million, with its median value being $7.7 million (2022).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first slumped by 72.47% in 2021, then skyrocketed by 459.13% in 2022.
  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses (Yearly) stood at $5.0 million in 2020, then tumbled by 72.47% to $1.4 million in 2021, then spiked by 459.13% to $7.7 million in 2022, then crashed by 35.07% to $5.0 million in 2023, then surged by 331.64% to $21.6 million in 2024.